Cargando…
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
INTRODUCTION: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achieving complete response (CR) is possible in many c...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603621/ https://www.ncbi.nlm.nih.gov/pubmed/37901197 http://dx.doi.org/10.1159/000529574 |
_version_ | 1785126642358681600 |
---|---|
author | Kudo, Masatoshi Aoki, Tomoko Ueshima, Kazuomi Tsuchiya, Kaoru Morita, Masahiro Chishina, Hirokazu Takita, Masahiro Hagiwara, Satoru Minami, Yasunori Ida, Hiroshi Nishida, Naoshi Ogawa, Chikara Tomonari, Tetsu Nakamura, Noriaki Kuroda, Hidekatsu Takebe, Atsushi Takeyama, Yoshifumi Hidaka, Masaaki Eguchi, Susumu Chan, Stephen L Kurosaki, Masayuki Izumi, Namiki |
author_facet | Kudo, Masatoshi Aoki, Tomoko Ueshima, Kazuomi Tsuchiya, Kaoru Morita, Masahiro Chishina, Hirokazu Takita, Masahiro Hagiwara, Satoru Minami, Yasunori Ida, Hiroshi Nishida, Naoshi Ogawa, Chikara Tomonari, Tetsu Nakamura, Noriaki Kuroda, Hidekatsu Takebe, Atsushi Takeyama, Yoshifumi Hidaka, Masaaki Eguchi, Susumu Chan, Stephen L Kurosaki, Masayuki Izumi, Namiki |
author_sort | Kudo, Masatoshi |
collection | PubMed |
description | INTRODUCTION: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achieving complete response (CR) is possible in many cases using curative conversion with resection, ablation, or superselective transarterial chemoembolization (TACE) with curative intent. This concept, i.e., curative conversion by combining systemic therapy and locoregional therapy, has not been reported before. This multicenter proof-of-concept study was conducted to show the value of curative conversion in immunotherapy-treated intermediate-stage HCC meeting TACE-unsuitable criteria. METHODS: This study included 110 consecutive Child-Pugh A patients who received atezolizumab plus bevacizumab as first-line treatment for unresectable and TACE-unsuitable intermediate-stage HCC at seven centers in Japan. CR rate, drug-free rate, time to CR, change in liver function, efficacy in positron emission tomography (PET)-positive HCC, progression-free survival (PFS), and overall survival (OS) were assessed in patients who achieved CR using resection, ablation, superselective TACE with curative intent following atezolizumab plus bevacizumab or atezolizumab plus bevacizumab alone. RESULTS: Clinical or pathological CR was achieved in 38 patients (35%) (median observation period: 21.2 months). The modalities of curative conversion in 35 patients were as follows: resection, 7; ablation, 13; and superselective TACE, 15. Three patients achieved clinical CR with atezolizumab plus bevacizumab therapy alone. Among the 38 CR patients, 25 achieved drug-free status. PFS was not reached, and 3 patients experienced recurrence after reaching CR. Regarding OS, there were no deaths in any of the CR patients. The albumin-bilirubin score did not deteriorate after locoregional therapy or resection. Of seven PET-positive patients who achieved CR with atezolizumab plus bevacizumab followed by curative conversion, five achieved drug-free status. CONCLUSION: The achievement of CR rate by curative conversion in patients treated with atezolizumab plus bevacizumab as the preceding therapy for unresectable and TACE-unsuitable intermediate-stage HCC was 35%. Overall, 23% of patients achieved drug-free status and no recurrence was observed from this patient subgroup with CR and drug-free status. Thus, achieving CR and/or drug-free status should be a therapeutic goal for patients with intermediate-stage HCC without vascular invasion or extrahepatic spread. |
format | Online Article Text |
id | pubmed-10603621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-106036212023-10-28 Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study Kudo, Masatoshi Aoki, Tomoko Ueshima, Kazuomi Tsuchiya, Kaoru Morita, Masahiro Chishina, Hirokazu Takita, Masahiro Hagiwara, Satoru Minami, Yasunori Ida, Hiroshi Nishida, Naoshi Ogawa, Chikara Tomonari, Tetsu Nakamura, Noriaki Kuroda, Hidekatsu Takebe, Atsushi Takeyama, Yoshifumi Hidaka, Masaaki Eguchi, Susumu Chan, Stephen L Kurosaki, Masayuki Izumi, Namiki Liver Cancer Research Article INTRODUCTION: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achieving complete response (CR) is possible in many cases using curative conversion with resection, ablation, or superselective transarterial chemoembolization (TACE) with curative intent. This concept, i.e., curative conversion by combining systemic therapy and locoregional therapy, has not been reported before. This multicenter proof-of-concept study was conducted to show the value of curative conversion in immunotherapy-treated intermediate-stage HCC meeting TACE-unsuitable criteria. METHODS: This study included 110 consecutive Child-Pugh A patients who received atezolizumab plus bevacizumab as first-line treatment for unresectable and TACE-unsuitable intermediate-stage HCC at seven centers in Japan. CR rate, drug-free rate, time to CR, change in liver function, efficacy in positron emission tomography (PET)-positive HCC, progression-free survival (PFS), and overall survival (OS) were assessed in patients who achieved CR using resection, ablation, superselective TACE with curative intent following atezolizumab plus bevacizumab or atezolizumab plus bevacizumab alone. RESULTS: Clinical or pathological CR was achieved in 38 patients (35%) (median observation period: 21.2 months). The modalities of curative conversion in 35 patients were as follows: resection, 7; ablation, 13; and superselective TACE, 15. Three patients achieved clinical CR with atezolizumab plus bevacizumab therapy alone. Among the 38 CR patients, 25 achieved drug-free status. PFS was not reached, and 3 patients experienced recurrence after reaching CR. Regarding OS, there were no deaths in any of the CR patients. The albumin-bilirubin score did not deteriorate after locoregional therapy or resection. Of seven PET-positive patients who achieved CR with atezolizumab plus bevacizumab followed by curative conversion, five achieved drug-free status. CONCLUSION: The achievement of CR rate by curative conversion in patients treated with atezolizumab plus bevacizumab as the preceding therapy for unresectable and TACE-unsuitable intermediate-stage HCC was 35%. Overall, 23% of patients achieved drug-free status and no recurrence was observed from this patient subgroup with CR and drug-free status. Thus, achieving CR and/or drug-free status should be a therapeutic goal for patients with intermediate-stage HCC without vascular invasion or extrahepatic spread. S. Karger AG 2023-02-07 /pmc/articles/PMC10603621/ /pubmed/37901197 http://dx.doi.org/10.1159/000529574 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Research Article Kudo, Masatoshi Aoki, Tomoko Ueshima, Kazuomi Tsuchiya, Kaoru Morita, Masahiro Chishina, Hirokazu Takita, Masahiro Hagiwara, Satoru Minami, Yasunori Ida, Hiroshi Nishida, Naoshi Ogawa, Chikara Tomonari, Tetsu Nakamura, Noriaki Kuroda, Hidekatsu Takebe, Atsushi Takeyama, Yoshifumi Hidaka, Masaaki Eguchi, Susumu Chan, Stephen L Kurosaki, Masayuki Izumi, Namiki Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study |
title | Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study |
title_full | Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study |
title_fullStr | Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study |
title_full_unstemmed | Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study |
title_short | Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study |
title_sort | achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603621/ https://www.ncbi.nlm.nih.gov/pubmed/37901197 http://dx.doi.org/10.1159/000529574 |
work_keys_str_mv | AT kudomasatoshi achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT aokitomoko achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT ueshimakazuomi achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT tsuchiyakaoru achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT moritamasahiro achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT chishinahirokazu achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT takitamasahiro achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT hagiwarasatoru achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT minamiyasunori achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT idahiroshi achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT nishidanaoshi achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT ogawachikara achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT tomonaritetsu achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT nakamuranoriaki achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT kurodahidekatsu achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT takebeatsushi achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT takeyamayoshifumi achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT hidakamasaaki achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT eguchisusumu achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT chanstephenl achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT kurosakimasayuki achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy AT izuminamiki achievementofcompleteresponseanddrugfreestatusbyatezolizumabplusbevacizumabcombinedwithorwithoutcurativeconversioninpatientswithtransarterialchemoembolizationunsuitableintermediatestagehepatocellularcarcinomaamulticenterproofofconceptstudy |